HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,173,693 | -15.7% | 213,971 | -20.4% | 0.02% | -19.0% |
| Q2 2023 | $9,696,734 | -8.0% | 268,831 | -2.6% | 0.02% | -19.2% |
| Q1 2023 | $10,545,366 | +201.2% | 276,129 | +348.7% | 0.03% | +160.0% |
| Q4 2022 | $3,501,455 | -25.8% | 61,537 | -48.5% | 0.01% | -28.6% |
| Q3 2022 | $4,721,000 | +1562.3% | 119,406 | +1588.9% | 0.01% | +1300.0% |
| Q4 2021 | $284,000 | -95.5% | 7,070 | -95.5% | 0.00% | -96.3% |
| Q3 2021 | $6,368,000 | -47.0% | 156,530 | -40.9% | 0.03% | -52.6% |
| Q2 2021 | $12,026,000 | +790.2% | 264,828 | +736.9% | 0.06% | +612.5% |
| Q4 2020 | $1,351,000 | +72.3% | 31,643 | -20.9% | 0.01% | +166.7% |
| Q1 2018 | $784,000 | +512.5% | 40,005 | +196.3% | 0.00% | +200.0% |
| Q1 2016 | $128,000 | -98.3% | 13,500 | -98.2% | 0.00% | -98.5% |
| Q4 2014 | $7,321,000 | – | 758,645 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |